---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-077306"
form_type: "8-K"
ticker: "PASG"
cik: "0001787297"
company_name: "Passage BIO, Inc."
filed_at: "2026-06-24T20:15:32+00:00"
generated_at: "2026-06-24T20:19:07.121497+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Passage Bio agrees to reverse merger with Remix; Remix equity value $226M; $100M concurrent financing

## Summary
- Remix ascribed equity value of $226M; Passage Bio's equity value ~$20M, subject to net cash adjustment at closing.
- Remix CEO Peter Smith, Ph.D., to lead combined company; Remix will designate all 9 board members.
- Remix stockholders owning ~93% of capital stock signed support agreements to vote in favor; $100M concurrent financing committed.
- Passage Bio terminates Catalent manufacturing agreement and PBFT02 license with Penn, winding down gene therapy programs.
- Passage Bio stockholders receive CVRs for potential proceeds from existing license agreements, but payments not assured.

## SEC filing metadata
- accession: 0001104659-26-077306
- form_type: 8-K
- ticker: PASG
- cik: 0001787297
- company_name: Passage BIO, Inc.
- filed_at: 2026-06-24T20:15:32+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 1.02, 3.02, 5.01, 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787297/000110465926077306/0001104659-26-077306-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787297/000110465926077306/tm2618476d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-077306
- JSON: https://secwatch.observer/filing/0001104659-26-077306.json
- Plain text: https://secwatch.observer/filing/0001104659-26-077306.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.